Citation: Eg. Brown et al., ADVERSE DRUG-REACTIONS OF THE MONTH - TIAPROFENIC ACID AND SEVERE CYSTITIS, Postgraduate medical journal, 74(873), 1998, pp. 443-444
Citation: Sjw. Evans et Pc. Waller, NEUROLOGICAL, CARDIOVASCULAR AND METABOLIC EFFECTS OF MEFLOQUINE IN HEALTHY-VOLUNTEERS - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, British journal of clinical pharmacology, 43(6), 1997, pp. 665-665
Citation: Js. Price et al., A COMPARISON OF THE POSTMARKETING SAFETY OF 4 SELECTIVE SEROTONIN REUPTAKE INHIBITORS INCLUDING THE INVESTIGATION OF SYMPTOMS OCCURRING ON WITHDRAWAL, British journal of clinical pharmacology, 42(6), 1996, pp. 757-763
Authors:
THOMAS SHL
BUTT AY
CORRIS PA
EGAN JJ
HIGENBOTTAM TW
MADDEN BP
WALLER PC
Citation: Shl. Thomas et al., APPETITE-SUPPRESSANTS AND PRIMARY PULMONARY-HYPERTENSION IN THE UNITED-KINGDOM, British Heart Journal, 74(6), 1995, pp. 660-663
Authors:
WALLER PC
WOOD SM
BRECKENRIDGE AM
RAWLINS MD
Citation: Pc. Waller et al., WHY THE SAFETY ASSESSMENT OF MARKETED MEDICINES (SAMM) GUIDELINES ARENEEDED, British journal of clinical pharmacology, 38(2), 1994, pp. 93-93
Citation: Pc. Waller, GUIDELINES FOR COMPANY-SPONSORED SAFETY ASSESSMENT OF MARKETED MEDICINES (SAMM GUIDELINES), British journal of clinical pharmacology, 38(2), 1994, pp. 95-97